StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) shareholders

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.18−0.23 (-5.22%)

Close on Nov 17, 2026Market cap $103.61MP/E –Yield –

Ownership

Who owns Lexaria Bioscience's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Richard ChristopherChief Executive Officer, Director65,0000.26%Jul 30, 2025
John Martin DochertyPresident & CSO, Director59,4510.24%Jul 30, 2025
Vanessa CarleSecretary7500.00%Jul 30, 2025
Michael Elliot ShankmanChief Financial Officer––May 16, 2025
Christopher BunkaDirector555,4552.24%Mar 18, 2026
William Edward McKechnieDirector18,1910.07%Jul 30, 2025
Albert L. Reese JrDirector10,9170.04%May 16, 2025
Nicholas W. BaxterDirector11,0000.04%May 16, 2025
Baljinder BhullarDirector13,0000.05%May 16, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Christopher Bunka
Director
Mar 17, 2026Gift−100,000––273,543
Christopher Bunka
Director
Jul 30, 2025Buy+11,900$0.91$10.83K281,912
Vanessa Carle
Secretary
Jul 29, 2025Buy+750$0.91$683750
Richard Christopher
Chief Executive Officer, Director
Jul 29, 2025Buy+15,000$0.91$13.65K65,000
William Edward McKechnie
Director
Jul 29, 2025Buy+5,000$0.91$4.55K18,191
John Martin Docherty
President & CSO, Director
Jul 29, 2025Buy+5,376$0.93$5.00K5,376
Christopher Bunka
Director
Jul 29, 2025Buy+15,600$0.92$14.35K270,012
Christopher Bunka
Director
Jan 7, 2025Award+100,000––373,543
Richard Christopher
Chief Executive Officer
Dec 3, 2024Buy+27,172$2.47$67.11K50,000
Richard Christopher
Chief Executive Officer
Dec 2, 2024Buy+22,828$2.24$51.13K22,828
Catherine C. Turkel
Director
Aug 12, 2024Buy+1,600$3.13$5.01K3,100
Vanessa Carle
Secretary
Jul 31, 2024Sale−2,567$4.00$10.27K0
Vanessa Carle
Secretary
May 14, 2024Option exercise+2,500$1.15$2.88K2,567
Catherine C. Turkel
Director
Feb 9, 2023Buy+1,500$2.84$4.26K1,500
Gregory Downey
Chief Financial Officer
Oct 14, 2022Buy+121$2.09$2531,954
Gregory Downey
Chief Financial Officer
Oct 14, 2022Award+121$2.09$2531,954
Christopher Bunka
Chief Executive Officer, Director
Oct 13, 2022Buy+16,600$2.10$34.86K254,412
Christopher Bunka
CEO, Director
Oct 13, 2022Award+16,600$2.10$34.86K254,412
Christopher Bunka
Chief Executive Officer, Director
Oct 12, 2022Buy+21,900$1.99$43.58K237,812
Christopher Bunka
CEO, Director
Oct 12, 2022Award+21,900$1.99$43.58K237,812
Albert L. Reese Jr
Director
May 24, 2022Award+5,000$1.96$9.80K10,917
Albert L. Reese Jr
Director
May 20, 2022Award+1,799$2.01$3.62K5,917
Albert L. Reese Jr
Director
May 19, 2022Award+1,501$2.01$3.02K4,118
Albert L. Reese Jr
Director
May 18, 2022Award+1,700$2.01$3.42K2,617
Christopher Bunka
CEO, Director, 10% owner
Nov 10, 2020Buy+10,000$0.20$2.00K6,445,844
Christopher Bunka
CEO, Director, 10% owner
Nov 10, 2020Buy+25,500$0.19$4.85K6,477,344
Christopher Bunka
CEO, Director, 10% owner
Nov 10, 2020Buy+6,000$0.20$1.20K6,451,844
Christopher Bunka
CEO, Director, 10% owner
Nov 9, 2020Buy+6,500$0.20$1.30K6,413,844
Christopher Bunka
CEO, Director, 10% owner
Nov 9, 2020Buy+22,000$0.20$4.40K6,435,844
Christopher Bunka
CEO, Director, 10% owner
Nov 9, 2020Buy+37,500$0.22$8.25K6,379,344
Christopher Bunka
CEO, Director, 10% owner
Nov 9, 2020Buy+10,000$0.20$2.00K6,389,344
Christopher Bunka
CEO, Director, 10% owner
Nov 9, 2020Buy+10,000$0.21$2.10K6,399,344
Christopher Bunka
CEO, Director, 10% owner
Nov 9, 2020Buy+8,000$0.20$1.60K6,407,344
Christopher Bunka
CEO, Director, 10% owner
Nov 6, 2020Buy+60,000$0.21$12.60K6,341,844
William Edward McKechnie
Director
Jul 23, 2020Option exercise+110,000$0.17$18.70K395,738
Christopher Bunka
CEO, Director, 10% owner
May 6, 2020Award+200,000$0.23$46.00K6,281,844
Nicholas W. Baxter
Director
Dec 20, 2019Option exercise+110,000$0.10$11.00K330,000
Allan Horst Spissinger
Chief Financial Officer
Feb 15, 2019Option exercise+50,000$0.37$18.50K119,116
John Martin Docherty
President, Director
Aug 31, 2018Award+36,500$2.07$75.56K1,622,250
Christopher Bunka
CEO, Director, 10% owner
Aug 31, 2018Award+32,500$2.07$67.28K7,126,304
Christopher Bunka
CEO, Director, 10% owner
Aug 14, 2018Gift−500,000––7,093,804
Christopher Bunka
CEO, Director, 10% owner
Aug 3, 2018Award+81,250$1.24$100.75K7,593,804
John Martin Docherty
Director, 10% owner
Aug 3, 2018Award+182,500$1.32$240.90K1,494,500
John Martin Docherty
Director, 10% owner
Aug 3, 2018Award+91,250$1.24$113.15K1,585,750
Christopher Bunka
CEO, Director, 10% owner
Jun 18, 2018Option exercise+247,500$0.09$22.28K7,512,554
Christopher Bunka
CEO, Director, 10% owner
Jun 18, 2018Option exercise+450,000$0.14$63.00K6,081,844
William Edward McKechnie
Director
May 31, 2018Sale−2,100$1.90$3.99K285,738
William Edward McKechnie
Director
May 30, 2018Sale−47,800$1.90$90.82K287,938
William Edward McKechnie
Director
May 30, 2018Sale−100$1.91$191287,838
Christopher Bunka
CEO, Director, 10% owner
Dec 1, 2017Award+29,475$0.82$24.17K7,265,054
Allan Horst Spissinger
CFO
Dec 1, 2017Award+41,666$0.82$34.17K69,166
William Edward McKechnie
Director
Dec 1, 2017Award+14,634$0.82$12.00K335,738
John Martin Docherty
Director, 10% owner
Dec 1, 2017Award+35,000$0.82$28.70K1,312,000
William Edward McKechnie
Director
Aug 28, 2017Award+32,433$0.37$12.00K321,104
John Martin Docherty
President, Director
Jun 22, 2017Award+210,000$0.30$63.00K1,277,000
Christopher Bunka
CEO, Director, 10% owner
Jun 21, 2017Award+210,000$0.30$63.00K5,631,844
William Edward McKechnie
Director
May 31, 2017Award+35,294$0.34$12.00K288,671
William Edward McKechnie
Director
May 31, 2017Award+35,249$0.34$11.98K288,626
William Edward McKechnie
Director
Feb 22, 2017Award+29,091$0.55$16.00K253,377
William Edward McKechnie
Director
Oct 11, 2016Award+114,286$0.14$16.00K224,286

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.90%
0M shares short
Days to cover
5.4
At 0M shares a day
Change since last report
-15.0%
From 0M shares
Short volume, 20 days
49.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lexaria Bioscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,550 shares on Sep 18, 2026 over the last 90 days.

See a number that looks wrong?